ivermectin oral / Generic mfg. 
Welcome,         Profile    Billing    Logout  
  Diseases    Trials    Trials    News 


«12...3132333435363738394041...129130»
  • ||||||||||  ivermectin oral / Generic mfg.
    First Nigerian Case Report of a Multi-Drug Resistant Kocuria Rosea in a Patient with Covid-19 (Exhibit and Poster Hall) -  Jun 4, 2022 - Abstract #ASMMicrobe2022ASM_Microbe_2495;    
    Biochemical microbiological testing techniques and systems may be inadequate in identifying emerging bacterial infections. The implication of this case report is the emergence of multi-drug resistant Kocuria rosea in Nigeria, which may necessitate screening for this bacterium in patients with co-morbidities and sepsis.
  • ||||||||||  ivermectin oral / Generic mfg.
    Clinical, Journal:  Outpatient prescription patterns of COVID-19 drugs in the metropolitan area of Mexico City. (Pubmed Central) -  Jun 4, 2022   
    Analysis of Google Trends showed a strong correlation between the overall number of confirmed COVID-19 cases and searches for such drugs, suggesting a higher rate of prescriptions. Analysis of online searches could thus help to actively survey public health behaviours in the future.
  • ||||||||||  ivermectin oral / Generic mfg.
    Review, Journal:  Adverse Audio-Vestibular Effects of Drugs and Vaccines Used in the Treatment and Prevention of COVID-19: A Review. (Pubmed Central) -  Jun 4, 2022   
    (3) In accordance with EBM (evidence-based medicine) the treatment of COVID-19 by using lopinavir/ritonavir, chloroquine and hydroxychloroquine, azithromycin, favipiravir, amantadine, oseltamivir, and ivermectin is no longer recommended for patients suffering from COVID-19 due to a lack of clinical data, publications, and recommendations...However, there is still a need to monitor ototoxic side-effects because of potential interactions with other ototoxic drugs. Many of the drugs approved by EMA and FDA are new, and not every side-effect is known.
  • ||||||||||  ivermectin oral / Generic mfg.
    Observational data, Journal:  Prescription for COVID-19 by non-medical professionals during the pandemic in Colombia: a cross-sectional study. (Pubmed Central) -  Jun 4, 2022   
    Given the massive release of misleading information during the pandemic, some pharmacies recommend drugs such as ivermectin, azithromycin, and hydroxychloroquine that are not useful for preventing or treating COVID-19 and could expose patients to unnecessary adverse drug reactions (ADRs), drug-drug interactions (DDIs), disease masking, and antibiotic resistance...Of 59 drugs suggested by pharmacies, the most recommended were azithromycin, ivermectin, acetaminophen, ibuprofen, and ASA (aspirin)...About 9.4% (26) of the establishments reported possible interactions of the recommended drugs and substances with food, beverages, or supplements. The majority of the pharmaceutical establishments included in the study promoted inadequate self-medication for COVID-19 in Colombia during the pandemic.
  • ||||||||||  ivermectin oral / Generic mfg.
    Clinical:  REMOVED: Treatment with Ivermectin Is Associated with Decreased Mortality in COVID-19 Patients: Analysis of a National Federated Database. (Pubmed Central) -  Jun 4, 2022   
    As in any retrospective study, we could not control for all the confounding variables, mainly severity of disease in patients treated with either ivermectin or remdesivir...Retrospective studies are only helpful to formulate hypothesis that can be utilized to design clinical trials. This misrepresentation of the study may lead to a huge public health problem, since Ivermectin is a medication that is not FDA approved for COVID treatment, and currently has proven to be ineffective in clinical trials, which are truly the gold standard to evaluate the efficacy of a medication.
  • ||||||||||  Veramyst (fluticasone furoate nasal spray) / GSK
    Trial primary completion date:  ACTIV-6: COVID-19 Study of Repurposed Medications (clinicaltrials.gov) -  May 30, 2022   
    P3,  N=15000, Recruiting, 
    control, WASH access and use should be improved to complement deworming programmes, and control efforts should ideally be expanded to entire communities. Trial primary completion date: Dec 2022 --> Mar 2023
  • ||||||||||  ivermectin oral / Generic mfg.
    Review, Journal, PARP Biomarker:  The Therapeutic and Prophylactic Potential of Quercetin against COVID-19: An Outlook on the Clinical Studies, Inventive Compositions, and Patent Literature. (Pubmed Central) -  May 30, 2022   
    The patent literature also examines claims that quercetin containing nutraceuticals, pharmaceuticals, and dietary supplements, alone or in combination with other drugs/compounds, including favipiravir, remdesivir, molnupiravir, navitoclax, dasatinib, disulfiram, rucaparib, tamarixin, iota-carrageenan, and various herbal extracts (aloe, poria, rosemary, and sphagnum) has potential for use against COVID-19...Quercetin is an acidic compound and shows metabolic interaction with some antivirals, antibiotics, and anti-inflammatory agents. Therefore, the physicochemical and metabolic drug interactions between quercetin and the combined drugs/compounds must be better understood before developing new compositions.
  • ||||||||||  ivermectin oral / Generic mfg.
    Journal:  Comprehensive diagnosis of parasites in sheep kept under different zootechnical management in a region temperate in Mexico. (Pubmed Central) -  May 29, 2022   
    No previous diagnosis is performed in flocks, and sometimes dewormers are administered, even though resistance to ivermectin and benzimidazole is suspected. Flock management, its feeding system and its conditions were determinant for the observed results; therefore, it is necessary to count with a diagnosis that provides information about the parasitic population and its dynamic, in order to carry out a selective and comprehensive control that has an impact on the animal, human and environmental health.
  • ||||||||||  ivermectin oral / Generic mfg.
    Retrospective data, Review, Journal:  COVID-19 and The Promise of Small Molecule Therapeutics: Are There Lessons to be Learnt? (Pubmed Central) -  May 26, 2022   
    The recent inclusion of molnupiravir and Paxlovid as treatment options for COVID-19 represent our best hope to date for endemic living with COVID-19. Our viewpoints on these two drugs and their prospects as current and future antiviral agents will also be provided.
  • ||||||||||  ivermectin oral / Generic mfg.
    Review, Journal:  Ivermectin as a possible treatment for COVID-19: a review of the 2022 protocols. (Pubmed Central) -  May 26, 2022   
    In addition, ivermectin has been used in mass treatment to prevent onchocerciasis and lymphatic filariasis in sub-Saharan Africa for many years. Surprisingly, this region has the lowest proportional mortality rate among the continents, despite the increasing numbers of infected people released by the World Health Organization.
  • ||||||||||  ivermectin oral / Generic mfg.
    Review, Journal:  A review on drug repurposing in COVID-19: from antiviral drugs to herbal alternatives. (Pubmed Central) -  May 25, 2022   
    Out of 11 repurposing drugs, four drugs are in status of emergency approval, most of them being in phase IV clinical trials. The first repurposing drug approved for clinical usage is remdesivir, whereas chloroquine and hydrochloroquine approval for emergency use was revoked by FDA for COVID-19 treatment in June 2020.
  • ||||||||||  ivermectin oral / Generic mfg.
    Journal, Adverse drug reaction:  Adverse drug reactions and ivermectin in COVID-19. (Pubmed Central) -  May 25, 2022   
    The first repurposing drug approved for clinical usage is remdesivir, whereas chloroquine and hydrochloroquine approval for emergency use was revoked by FDA for COVID-19 treatment in June 2020. No abstract available
  • ||||||||||  ivermectin oral / Generic mfg.
    Observational data, Journal:  Self-medication in hospitalized patients with COVID-19: A cross-sectional study in northern Peru. (Pubmed Central) -  May 24, 2022   
    Out of 301 patients, 165 (54.8%) self-medicated before hospital admission, being more frequent self-medication with ivermectin (85.5%) and azithromycin (71.5%)...Clinical characteristics associated with self-medication were fever, cough, headache, anosmia, dysgeusia, nausea/vomiting, and gastroesophageal reflux. A high frequency of self-medication before hospital admission was observed in Peruvian patients with COVID-19, mainly of drugs without proven efficacy.